Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: David Howe who wrote (3738)	10/6/1999 11:06:00 AM
From: Biomaven	Read Replies (1) \| Respond to of 10280

Dave, The FTC investigation seems to be dragging on longer than predicted. As I understand it, the ball is currently in LLY's court, so not much SEPR can do to speed things up. Given the FTC didn't whine about Claritin, it's hard for me to see why Prozac is different. OTOH, the FTC seems to be getting more aggressive in the drug area. I can't believe they'd block the deal. Conceivably they might demand some restrictions on marketing - no claims that it's the "new, improved Prozac" or the like. Bottom line is that the investigation is an irritant and causes uncertainty, which hurts the stock price as long as it's still ongoing. Conceivably some other deals with SEPR might also be held up while everyone waits to see exactly how it turns out. Peter